☆ 4.7 Article

Nodal Pathologic Complete Response Rates in Luminal Breast Cancer Vary by Genomic Risk

ANNALS OF SURGICAL ONCOLOGY (2022)

Related references

Note: Only part of the references are listed.

Article Oncology

Neoadjuvant Chemotherapy and Nodal Response Rates in Luminal Breast Cancer: Effects of Age and Tumor Ki67

Judy C. Boughey et al.

Summary: In ER+/HER2- breast cancer, nodal downstaging with NAC is associated with age (< 50 years) and Ki67 (>= 20%). Age and Ki67 should be considered for NAC decision-making and can identify patients with high rates of nodal downstaging (36%) who would benefit from NAC to enable axillary preservation.

ANNALS OF SURGICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update

Fabrice Andre et al.

Summary: This article provides updated recommendations on the appropriate use of breast cancer biomarker assay results in guiding adjuvant endocrine and chemotherapy decisions for early-stage breast cancer. Based on the latest literature and expert consensus, specific biomarker assay results can be used to guide treatment decisions for patients who meet certain criteria. However, other factors such as disease stage, comorbidities, and patient preferences should also be considered.

JOURNAL OF CLINICAL ONCOLOGY (2022)

Add to Collection

Article Oncology

The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer

Roberto A. Leon-Ferre et al.

Summary: Neoadjuvant chemotherapy has become the preferred approach for most HER2-positive and triple-negative breast cancers, with initial motivations being to decrease surgical extent and advance drug development, recent trials have shown survival advantages from escalating systemic treatment in patients with residual disease.

ANNALS OF SURGICAL ONCOLOGY (2021)

Add to Collection

Article Medicine, General & Internal

21-Gene Assay to Inform Chemotherapy Benefit in Node-Positive Breast Cancer

Kevin Kalinsky et al.

Summary: The study showed that among premenopausal women with hormone-receptor-positive, HER2-negative breast cancer and one to three positive lymph nodes with a recurrence score of 25 or lower, the addition of chemotherapy to endocrine therapy led to longer invasive disease-free survival and distant relapse-free survival compared to endocrine therapy alone. However, postmenopausal women with similar characteristics did not benefit from adjuvant chemotherapy in terms of invasive disease-free survival.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Oncology

Breast Cancer, Version 3.2018 Featured Updates to the NCCN Guidelines

Matthew P. Goetz et al.

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2019)

Add to Collection

Article Medicine, General & Internal

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

G. von Minckwitz et al.

NEW ENGLAND JOURNAL OF MEDICINE (2019)

Add to Collection

Article Oncology

Neoadjuvant Chemotherapy Use in Breast Cancer is Greatest in Excellent Responders: Triple-Negative and HER2+Subtypes

Brittany L. Murphy et al.

ANNALS OF SURGICAL ONCOLOGY (2018)

Add to Collection

Article Medicine, General & Internal

Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer

J. A. Sparano et al.

NEW ENGLAND JOURNAL OF MEDICINE (2018)

Add to Collection

Article Medicine, General & Internal

Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy

N. Masuda et al.

NEW ENGLAND JOURNAL OF MEDICINE (2017)

Add to Collection

Article Oncology

The Optimal Treatment Plan to Avoid Axillary Lymph Node Dissection in Early-Stage Breast Cancer Patients Differs by Surgical Strategy and Tumor Subtype

Melissa Pilewskie et al.

ANNALS OF SURGICAL ONCOLOGY (2017)

Add to Collection

Article Medicine, General & Internal

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

F. Cardoso et al.

NEW ENGLAND JOURNAL OF MEDICINE (2016)

Add to Collection

Article Surgery

Tumor Biology Correlates With Rates of Breast-Conserving Surgery and Pathologic Complete Response After Neoadjuvant Chemotherapy for Breast Cancer Findings From the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial

Judy C. Boughey et al.

ANNALS OF SURGERY (2014)

Add to Collection

Article Medicine, General & Internal

Sentinel Lymph Node Surgery After Neoadjuvant Chemotherapy in Patients With Node-Positive Breast Cancer The ACOSOG Z1071 (Alliance) Clinical Trial

Judy C. Boughey et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2013)

Add to Collection

Article Oncology

Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study

Thorsten Kuehn et al.

LANCET ONCOLOGY (2013)

Add to Collection

Article Oncology

Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer

Soonmyung Paik et al.

JOURNAL OF CLINICAL ONCOLOGY (2006)

Add to Collection

© Peeref 2019-2024. All rights reserved.